Our Company Resources

Resources

Articles

View all

Solutions for Mitigating Challenges in Recombinant Protein Production

Preclinical Model of Post – Incisional Pain for Efficacy Testing of Novel Therapeutics

Manual Whole-Cell Patch Clamp Assay for Screening NCE’s Against Voltage Gated Ion-Channels

Clinically relevant preclinical model of CFA-Induced inflammatory pain

A Comparative Efficiency Analysis of Commercial Transfection Reagents in HEK 293 Cells

Accelerating the regulatory approval process of biosimilars by leveraging precise and reliable PK data and PD biomarker data

Experimental Chronic Constriction Injury (CCI)- induced Neuropathic Pain Model Aragen Life Sciences

Aragen’s quantitative proteomics sampling capabilities: Accurate and Reproducible Workflows

Experimental pain models at Aragen Life Sciences – Spinal Nerve Ligation (SNL) Model of Neuropathic Pain

Pharmacokinetics (PK)/ Pharmacodynamics (PD) and Mechanistics solutions in Ellegaard Göttingen Minipigs

Comprehensive Characterization of Biologics

Drug-Protein Interaction: Limitless Application of Mass spectrometry in Target Engagement, Intact Mass and Peptide Mapping Analysis.

Automation to miniaturize In vitro assays to achieve superior and cost-efficient results

Targeted Protein Degradation

Pharmacokinetic study of Salbutamol through nose only exposure in CD-1 male mice

Cell line development capabilities

Cell line development comprehensive solutions

Aragen’s Bleomycin-Induced Scleroderma mouse model for preclinical testing of novel therapeutics

Industry Leading Hybridoma Technique for Accelerated Antibody Discovery

Covalent Drugs – Advantages, Challenges, And Opportunities

Mitigating CMC issues through Aragen’s holistic approach to developability assessment

Aragen’s Preclinical Oncology Capabilities – Tumor Imaging

Preclinical evaluation of Novel drug candidates against SLE in NZB/W F1 mouse models

Aragen’s Oncology solutions: Accelerate your cancer therapeutics development

RSV Challenge Model for anti-RSV therapy

Cell Line Development at Aragen: Research cell banks in 5 months

Effect of Methylprednisolone on the Systemic lupus erythematosus (SLE) in murine models

DSS-induced IBD Mouse Model for preclinical drug screening

Cell Line Development at Aragen; Accelerating speed to IND

View all

Brochures

View all

Your partner for timely, accurate and high-quality preclinical efficacy studies

Gene to GMP: First-in-human in 8 Months with Optimized Cost

Navigating Recombinant Protein Production– Leveraging Aragen’s Multifaceted Expression Systems

Modalities for Mechanistic Exploration in Agrochemical Solutions

Paclitaxel-induced Peripheral Neuropathic Pain Model Developed at Aragen

Comprehensive Services for Immersive Corrosion Testing of Metals and Alloys Across a Wide Spectrum of Test Subjects

Comprehensive In-Vitro Microbial Kill Rate Studies for screening antimicrobial agents

Exploring Molecular Interactions Through Surface Plasmon Resonance

Experimental λ-Carrageenan-induced inflammatory pain model for testing novel analgesics

Genetic and Alternative Toxicity Testing for Compound Screening, Derisking and Selection

Comprehensive Solutions for Animal Health Biologics

Aragen Cell Line Development Solutions for Biologics CHO CLD Platforms

Phosphonamidite

Oligonucleotides

Flow Chemistry

Specialized Services in Custom Peptide Synthesis (Solution Phase)

Comprehensive DoE capabilities for Synthesis, Process Development and Manufacturing of Novel Chemical Entities (NCE’s)

Nitrosamine Risk Assessment

Comprehensive GLP regulated Ecotoxicology Services

Comprehensive and Regulated “Developmental and Reproduction Toxicology (DART)” studies

Intox Safety Assessment

Preclinical Safety Evaluation and Clinical Bioanalysis Services for Vaccines

Nonclinical Safety Assessment of New Biological Entities (NBEs)

Process Safety, Dust Explosion Testing Capabilities

Aragen Overview

Your Partner for Chemocatalysis Solutions

Nonclinical Safety Assessment of New Chemical Entities (NCE)

Aragen protein science solutions: Industry leading upstream and downstream capabilities

Highly Potent Active Pharmaceutical Ingredients (HPAPIs)

Biocatalysis Solutions

Streptozotocin-induced Diabetic Peripheral Neuropathic Pain Model Developed at Aragen

Targeted Protein Degradation Solutions

Aragen’s Preclinical Oncology Capabilities

Preclinical Evaluation of new Antifibrotics in IPF Rodent Models

Pharmacokinetic (PK) solutions in large animals

Formulation Solutions

Discovery Biology Solutions

ADME – DMPK Solutions

Extractables and Leachables Solutions

In Vitro Pharmacology Solutions

In Vivo Pharmacology Solutions

Nitrosamine Impurity Detection and Quantification

TOXVIT – Aragen In Vitro Toxicology Solutions

ICP-MS

Protein Analytics Solutions

Peptide Chemistry Solutions

API and Intermediates

Integrated Drug Discovery Solutions

Discovery Chemistry Solutions

Developability and Analytics Solutions

Contract Manufacturing Solutions

Integrated Cell Line Development Solutions

Small Molecule Process R&D and Manufacturing Solutions

Amylin Liver NASH (AMLN)

View all

Case Studies

View all

Redefine In silico Predictions with High-throughput LC-MS/MS LogD Analysis

Unravelling Immunological Depths: Exploring Oxazolone-induced Delayed-Type Hypersensitivity Model

Unlocking Insights: A Translational Mouse Model for Non-Genetic Heterotopic Ossification

A Preclinical Efficacy Study using Diet induced Obesity Mice Model

Designing an optimal and scalable protocol for formulating a 40% emulsifiable concentrate for a systemic insecticide

Developing a thermodynamically stable microemulsion with fine droplet size for delivering a highly lipophilic drug with limited intestinal permeability

Elevating Purity Levels: Racemizing Pharmaceutical Products in Advanced Flow Microreactors

Modelling Targeted Protein Degraders (TPDs) Utilizing Computational and Medicinal Chemistry Approaches

A robust and scalable strategy to develop monodisperse Nanosuspension formulation for a poorly soluble drug substance

A robust and scalable strategy to develop amorphous solid dispersion formulation for a poorly soluble drug substance

Comprehensive Preclinical Development Program for a COVID mRNA Vaccine

Expression, in vivo Maturation and Tag-less Purification of a Recombinant Protein

Alcoholic Steatohepatitis Model – CDAHFD

Consistency of Bleomycin-induced pulmonary fibrosis

Pro-inflammatory chemokines measured in bronchoalveolar lavage fluid (BALF)

Consistency of fibrotic induction in lungs from multiple studies

Non-Alcoholic Steatohepatitis Model

Treatment of CDAHFD-induced NASH mice with Elafibranor

Showing the readouts using the above-mentioned protocol

CS – Oncology 1

CS – Oncology 2

CS – Oncology 3

CS – Oncology 4

An optimal upstream process development approach to increase the titers of the monoclonal antibodies (mAbs)

Enabling Formulation Development for Toxicology Studies for a New Chemical Entity

Physical Form Selection of a Small Molecule

View all

On-demand Webinars

View all

PROTACs: Breaking Boundaries in Drug Discovery

Process Development of New Chemical Entities — Overcoming Challenges of Safety and Quality for a Seamless Technology Transfer

Amorphous Solid Dispersion — An Ideal Formulation Approach to Improve Developability of Poorly Soluble Molecules

Accelerating Vaccines to Clinical Trials — A Toolkit for Efficacy, Safety and Bioanalytical Studies

Upstream Process Development for Better Yield and Product Quality

The Role of Protein Analytics in the Advancement of Biotherapeutic Drug Discovery & Development

Driving Better Titers and Shorter Timelines with a Robust and Scalable CHO DG44 Platform

Brain Metastases – Challenges of Developing Clinically Relevant Preclinical Models

Development of Covalent Drugs with New Emerging Technologies

Accelerating Biologics Development to Medicines: Key Drivers of Success

Targeted Protein Degradation in Inflammation and Cancer Therapy

Enabling Clinical Development of Poorly Soluble Molecules Through Formulation Solutions

View all

Posters

View all

Therapeutic Impact of an ALK5 Inhibitor Across Multiple Preclinical Fibrosis Models

Enhancing mAb platform process using Membrane chromatography (Affinity/Protein-A, using Sartobind Rapid A) for FIH molecules with focus on Optimizing cost and Accelerating timelines

Decoding the Conformational Plasticity of Ternary Complexes for Protacs’ Differential Activity

In vitro phototoxicity validation study

Reliable and Reproducible Preclinical Rodent Models of MAS

Phenotypic Characterization of Bleomycin-Induced Pulmonary Fibrosis Model

Column Head Loading in SFC

Blood Brain Permeability and CNS Bioavailability

In vitro/In vivo Correlation of Permeability

View all

Whitepapers

View all

From Molecular Pharmaceutics to Scalable Manufacturing: CRDMO Expertise in Spray Dried Dispersions

Pharmacokinetic Assessment and Anti-Drug Antibodies Assessment of GLP-1 Receptor Agonists

Enhancing Biopharmaceutical Manufacturing with Single-Use Bioreactors: A Transformative Solution for CRDMO Operations

Revolutionizing new drug discovery- Harnessing AI ML Tools

Preclinical Evaluation of Vaccines and Antivirals in RSV Challenge Rodent Models

Preclinical Evaluation of new Antifibrotics in NASH-Induced Fibrosis Models

Preclinical Evaluation of new Antifibrotics in Corona mouse Virus-Induced Fibrosis Model

Preclinical Evaluation of new Antifibrotics in IPF Rodent Models

Preclinical evaluation of vaccines and antivirals in RSV challenge SCID mouse models

Preclinical evaluation of vaccines and antivirals in RSV challenge in BALB/c Mouse models

Flow Chemistry vs. Batch Processes

A Novel Cell-based Screening Assay for Cholesterol Biosynthetic Pathway Inhibition Using the RapidFire HTMS Platform

A Highly Reproducible In Vivo Model for Bleomycin-Induced Lung Fibrosis in Mice to Evaluate Drugs for the Treatment of Idiopathic Pulmonary Fibrosis

Pharmacokinetic Strategies in CNS Drug Discovery

View all

Virtual Tours

View all

Discovery Chemistry

Analytical Chemistry

In Vitro Pharmacology - Assay Development & Screening

In Vitro Pharmacology - Toxicology

In Vivo Pharmacology

DMPK

Cell and Protein Sciences

Process Safety

Analytical Development

Analytical Solutions

Formulation

Process Engineering

QC

Biologics

View all

Videos

View all

Aragen’s Kilo Lab

Analytical Research Facility

Manufacturing Unit at Hyderabad, India

Formulations Manufacturing Facility

Vivarium Facility at Bangalore, India

Discovery Biology R&D Facilities

Manufacturing Facility at Visakhapatnam, India

Discovery Chemistry Facilities

Tox Services – Capabilities and Infrastructure

Blogs

View all

What are peptides? Functions, Types & Synthesis Methods

Exploring Oligonucleotide Synthesis: A Catalyst for Precision Medicine, Gene Editing and Beyond

The Power of Integrated Drug Discovery Solutions: Enhancing Efficiency and Innovation in Drug Development

What is Pharmaceutical Formulation Development?

What are the Roles of Genomics and Proteomics in Drug Discovery and Personalized Medicine?

What is Structural Biology?

What is Medicinal Chemistry in Drug Discovery?

The Essential Role of Analytical Chemistry in the Pharmaceutical Industry

Overcoming Challenges in Chemical Engineering during Pharmaceutical Scale-Up

Optimizing Pharmaceutical Processes and Enhancing Biological Experimental Design Efficiency with Design of Experiments Methodology

The Role of Green Chemistry in Driving Success in Chemical Innovations

What is Lead Optimization in Drug Discovery?

What is Lead Identification in Drug Discovery?

What is High-Throughput Screening in Drug Discovery

What is Biologics Development?

Innovative Solutions: Overcoming Chemical Synthesis Hurdles in the Global CDMO Landscape

Navigating Growth: Challenges and Opportunities in the Small Molecule CDMO Sector

The Synergy of Services: How CDMOs Drive Innovation in Medicinal Chemistry?

CDMOs: Pioneering Partnerships in Immuno-Oncology Drug Development

What is Protein Science?

What is Antibody Discovery?

What is Molecular Biology?

What are Performance Chemicals?

The Rise of High Potent APIs: Trends, Technologies, and Manufacturing Best Practices

CDMO Innovations: Advancing Pharma Manufacturing with Chemical Development Solutions From Early To Late Phase

Maximizing Efficiency: How High-Throughput Screening Services Drive Drug Discovery

Streamlining Small Molecule Drug Development: The Advantages of Integrated CDMOs

Integrated Drug Discovery: Streamlining Therapeutic Solutions

Understanding Drug Safety and Efficacy: Key Concepts & Processes

What is Drug Interaction? Types, Symptoms, and Prevention

What Are Peptides – Their Functions, Advantages & Where Are They Used?

What’s Driving the Booming Market of Oligonucleotide Synthesis, Nationally and Globally

Why Integrated Service Offerings Matter in the Pharmaceutical Industry?

Biologics vs. Small Molecules: Critical Drug Development Insights

Reimagining Medicine with PROTACS – A Bold Vision for Future Therapies

×

Contact An Expert Today!